After parting ways with BeiGene in 2023, Novartis effectively bowed out of the PD-1 race. | The rising class of bisepcifics ...

Just a few years ago, children with Type 1 diabetes reported to the school nurse several times a day to get a finger pricked ...

The imaging artificial intelligence developer Quibim has raised $50 million in venture capital funding, to support its work ...

The drug in question, called firicabtagene autoleucel or firi-cel, is an autologous CD22 CAR-T cell therapy that had been ...

All nine macaques given the control developed severe disease when exposed to bird flu, as did all given the smallest dose of ...

Takeda has axed plans to seek approval for its failed epilepsy drug candidate soticlestat. The Japanese drugmaker pulled the ...

Sanofi has removed a clutch of programs from its clinical pipeline, scratching out entries for its late-phase BTK inhibitor and phase 1 prospects linked to the multibillion-dollar takeovers of Ablynx, ...